JP5554770B2 - 子ブタにおけるヘモフィルス・パラスイス血清型4に対する防御のためのワクチン - Google Patents
子ブタにおけるヘモフィルス・パラスイス血清型4に対する防御のためのワクチン Download PDFInfo
- Publication number
- JP5554770B2 JP5554770B2 JP2011501213A JP2011501213A JP5554770B2 JP 5554770 B2 JP5554770 B2 JP 5554770B2 JP 2011501213 A JP2011501213 A JP 2011501213A JP 2011501213 A JP2011501213 A JP 2011501213A JP 5554770 B2 JP5554770 B2 JP 5554770B2
- Authority
- JP
- Japan
- Prior art keywords
- serotype
- bacteria
- vaccine
- haemophilus parasuis
- sows
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229960005486 vaccine Drugs 0.000 title claims description 36
- 241000606790 Haemophilus Species 0.000 title claims description 5
- 241000606807 Glaesserella parasuis Species 0.000 claims description 48
- 241000894006 Bacteria Species 0.000 claims description 27
- 238000002255 vaccination Methods 0.000 claims description 16
- 210000003022 colostrum Anatomy 0.000 claims description 11
- 235000021277 colostrum Nutrition 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000037406 food intake Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 241000282887 Suidae Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 6
- 230000005856 abnormality Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 208000005342 Porcine Reproductive and Respiratory Syndrome Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 239000006792 cys medium Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000000653 nervous system Anatomy 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 238000011886 postmortem examination Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013647 Drowning Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
5頭の成熟雌ブタ(SPFブタ、ヘモフィルス・パラスイス(H.parasuis))に、商業的に入手可能なワクチンPorcilis Glasser DFを分娩予定日の6〜8週間前(筋肉内、2ml)および4週間後(再び筋肉内、2ml)にワクチン接種した。このワクチンは、Schering−Plough Corporation,Boxmeer,the Netherlandsの一部であるIntervet B.V.から入手可能である。該ワクチンはヘモフィルス・パラスイス(Haemophilus parasuis)血清型5細菌のホルムアルデヒド不活化全細胞を含み、該活性成分はDiluvac Forte(水中油)アジュバントに懸濁されている。一般に、ヘモフィルス・パラスイス(Haemophilus parasuis)血清型5抗原を含む任意の他のワクチンは、基本的には、ヘモフィルス・パラスイス(H.parasuis)(生または不活化、全細胞、抽出物、精製画分または更にはサブユニット)の適当な抗原を、医薬上許容される担体、例えば液体担体、例えば(場合によっては緩衝化された)水または固体担体、例えば、凍結乾燥ワクチンを得るために一般に使用されるものと混合することを含む、当技術分野で公知の方法を用いることにより製剤化されうる。場合によっては、該ワクチンの意図される用途または要求される特性に応じて、他の物質、例えばアジュバント、安定剤、粘度改変剤または他の成分が加えられる。本実施例においては、本発明者らは前記の商業的に入手可能なワクチンを使用した。
0=正常、
1=食欲不振、
2=食欲不振およびうつ状態、
3=機能低下および起立が遅い、
4=瀕死。
0=正常な挙動、
1=腫脹、熱または疼痛を伴う関節、
2=1以上の足の跛行、
3=地面に足を着けることができない、
4=瀕死でない場合に起立を拒む。
0=正常な挙動、
1=傾いた頭、
2=平衡喪失、
4=痙攣。
0=異常なし、
2=軽度の異常、
4=安楽死を要する重度の異常。
成熟雌ブタは、ポルシリス・グレーサー(Porcilis Glasser)でのワクチン接種の後のヘモフィルス・パラスイス(H.parasuis)に対する血清価の良好な増加を示した。第1ワクチン接種前に8.4 log2の血清価を有していたワクチン接種群の1頭の成熟雌ブタを除き、ワクチン接種前には全ての成熟雌ブタの血清価は6.7 log2未満であった。分娩直前の血清価はワクチン接種成熟雌ブタでは8.6〜12.6 log2の範囲であったが、未ワクチン接種成熟雌ブタの力価はELISAの検出限界未満(<6.7 log2)のままであった。ワクチン接種成熟雌ブタの初乳における力価は9.0〜>13.7 log2の範囲であったが、未ワクチン接種成熟雌ブタの初乳における力価は<6.6〜7.9 log2の範囲であった。4週齢において、各成熟雌ブタからの2頭の子ブタをヘモフィルス・パラスイス(H.parasuis)血清型4でチャレンジした。結果を表1に示す。
Claims (5)
- ヘモフィルス・パラスイス(Haemophilus parasuis)血清型4細菌から生じる障害に対して分娩後の成熟雌ブタまたは若雌ブタの初乳の摂取により子ブタを防御するために妊娠中の成熟雌ブタまたは若雌ブタに投与するためのワクチンの製造におけるヘモフィルス・パラスイス(Haemophilus parasuis)血清型5細菌の使用。
- 該ワクチンがヘモフィルス・パラスイス(Haemophilus parasuis)血清型5細菌の不活化細胞および/またはヘモフィルス・パラスイス(Haemophilus parasuis)血清型5細菌の非生成分を含む、請求項1記載の使用。
- 該成熟雌ブタまたは若雌ブタの第1ワクチン接種の後、第2ワクチン接種を行い、該成熟雌ブタまたは若雌ブタが分娩する前に第1および第2ワクチン接種を行う、請求項1又は2記載の使用。
- 分娩予定日の6〜8週間前に第1ワクチン接種を行い、分娩予定日の2〜4週間前に第2ワクチン接種を行う、請求項3記載の使用。
- 子ブタをヘモフィルス・パラスイス(Haemophilus parasuis)血清型4細菌から生じる障害に対して防御するための、ヘモフィルス・パラスイス(Haemophilus parasuis)血清型5細菌を含むワクチンであって、妊娠中の成熟雌ブタまたは若雌ブタに投与され、分娩後の前記成熟雌ブタまたは若雌ブタの初乳の摂取により、その子ブタがヘモフィルス・パラスイス(Haemophilus parasuis)血清型4細菌から生じる障害に対して防御される、ワクチン。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3959008P | 2008-03-26 | 2008-03-26 | |
EP08153290 | 2008-03-26 | ||
EP08153290.5 | 2008-03-26 | ||
US61/039,590 | 2008-03-26 | ||
PCT/EP2009/053490 WO2009118330A1 (en) | 2008-03-26 | 2009-03-25 | Vaccine for protection against haemophilus parasuis serotype 4 in piglets |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011515442A JP2011515442A (ja) | 2011-05-19 |
JP5554770B2 true JP5554770B2 (ja) | 2014-07-23 |
Family
ID=39711791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011501213A Active JP5554770B2 (ja) | 2008-03-26 | 2009-03-25 | 子ブタにおけるヘモフィルス・パラスイス血清型4に対する防御のためのワクチン |
Country Status (8)
Country | Link |
---|---|
US (1) | US20110014237A1 (ja) |
EP (1) | EP2280725B1 (ja) |
JP (1) | JP5554770B2 (ja) |
BR (1) | BRPI0908884A2 (ja) |
DK (1) | DK2280725T3 (ja) |
ES (1) | ES2386756T3 (ja) |
RU (1) | RU2498816C2 (ja) |
WO (1) | WO2009118330A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201043242A (en) * | 2009-03-26 | 2010-12-16 | Intervet Int Bv | Vaccine for protection against Streptococcus suis bacteria of various serotypes |
WO2011131789A1 (en) | 2010-04-23 | 2011-10-27 | Intervet International B.V. | A vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5 |
CN102399724B (zh) * | 2011-11-08 | 2013-01-02 | 山东省农业科学院畜牧兽医研究所 | 一种副猪嗜血杆菌lc株及其应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6342231B1 (en) * | 1998-07-01 | 2002-01-29 | Akzo Nobel N.V. | Haemophilus parasuis vaccine and diagnostic |
RU2269570C2 (ru) * | 2004-04-21 | 2006-02-10 | Федеральное государственное учреждение "Федеральный центр охраны здоровья животных" (ФГУ ВНИИЗЖ) | Штамм haemophilus parasuis ил-1 - возбудитель гемофилезного полисерозита свиней для изготовления диагностических и вакцинных препаратов |
US8404253B2 (en) * | 2006-12-28 | 2013-03-26 | Newport Laboratories, Inc. | Modified live (JMSO strain) Haemophilus parasuis vaccine |
-
2009
- 2009-03-25 EP EP09724781A patent/EP2280725B1/en active Active
- 2009-03-25 BR BRPI0908884A patent/BRPI0908884A2/pt not_active Application Discontinuation
- 2009-03-25 WO PCT/EP2009/053490 patent/WO2009118330A1/en active Application Filing
- 2009-03-25 DK DK09724781.1T patent/DK2280725T3/da active
- 2009-03-25 JP JP2011501213A patent/JP5554770B2/ja active Active
- 2009-03-25 ES ES09724781T patent/ES2386756T3/es active Active
- 2009-03-25 RU RU2010143584/10A patent/RU2498816C2/ru active
- 2009-03-25 US US12/933,846 patent/US20110014237A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2280725B1 (en) | 2012-05-23 |
DK2280725T3 (da) | 2012-09-10 |
US20110014237A1 (en) | 2011-01-20 |
RU2498816C2 (ru) | 2013-11-20 |
EP2280725A1 (en) | 2011-02-09 |
RU2010143584A (ru) | 2012-05-10 |
WO2009118330A1 (en) | 2009-10-01 |
JP2011515442A (ja) | 2011-05-19 |
ES2386756T3 (es) | 2012-08-29 |
BRPI0908884A2 (pt) | 2015-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10953088B2 (en) | Vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus | |
JP5651677B2 (ja) | 各種血清型のブタ連鎖球菌(Streptococcussuis)細菌から防御するためのワクチン | |
ES2630023T3 (es) | Vacuna de lawsonia y métodos de uso de la misma | |
JP6931059B2 (ja) | 豚用混合ワクチン | |
BRPI0608439B1 (pt) | vacinas combinadas compreendendo lawsonia intracellularis, salmonella spp e erysipelothrix rhusiopathiae, e kits | |
TW200927166A (en) | Mycoplasma hyopneumoniae avirulent-adjuvanted live vaccine | |
JP5789897B2 (ja) | マイコプラズマ・ボビス ワクチン | |
EP2561063B1 (en) | A vaccine comprising inactivated cells of haemophilus parasuis bacteria of serotype 5 | |
AU782508B2 (en) | Vaccines for mycoplasma bovis and methods of use | |
US10568954B2 (en) | Process for ready-to-use PCV/M.Hyo combination vaccine | |
JP2013223511A6 (ja) | マイコプラズマ・ボビス ワクチン | |
JP2011500093A6 (ja) | マイコプラズマ・ボビス ワクチン | |
EP2029166A2 (en) | Vaccination of young animals against lawsonia intracellularis infections | |
JP5554770B2 (ja) | 子ブタにおけるヘモフィルス・パラスイス血清型4に対する防御のためのワクチン | |
CN105873604B (zh) | 针对prrs和胞内劳森氏菌的猪疫苗 | |
KR20200100055A (ko) | 연쇄상구균에 대한 보호를 위한 백신 | |
NL2018155B1 (en) | Oral vaccine against ruminant respiratory disease | |
Dungu | Assessment of vaccine delivery systems and their impact on the enhancement of immunogenicity, potency and safety of specific livestock vaccines used in South Africa | |
JP2019535786A (ja) | ブタワクチン | |
KR20120103583A (ko) | 액티노바실러스 수이스 항원 | |
JP2023113631A (ja) | クロストリジウム類毒素を含むワクチン | |
NZ795066A (en) | Oral vaccine against ruminant respiratory disease comprising polyvinylpyrrolidone |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120322 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130903 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140520 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140529 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5554770 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |